Alert...bought shares of POSC.OB at .195 in the Established & Starter Portfolio. Biomed Reports discussed this medical play this morning in a subscriber alert. The last play they had (RPC) was alerted at .30 and went to $2.60 as I watched on the sidelines and never got in. That won’t happen here! I have been watching POSC the past few days and the stock has gotten stronger. The company has an outstanding product (Frost & Sullivan Award winner in 2010) that could potentially lure a suitor to the company in the wake of all the Medicare cuts that Congress will shortly impose. This sector and the POSC product will allow for additional revenue streams allowing another medical company to potentially sell the POSC FDA cleared medical devices to clinics. Every now and then I will highlight a bio/medical lotto play with significant potential. This is a good medical lotto play for me that I think has a lot of potential here very soon! I think it can get into the dollar range if they can find a suitor for their Frost & Sullivan 2010 award-winning product! The changes in Medicare that will occur in June make this a strong possibility IMO. Enter at your own risk but I like the risk/reward potential here. DD posts on the products potential in the Oncology, Cardiology, and other medical specialties will follow $heff
Sheff's Station...All Aboard...Sign Up Here!
